Blog

  • How Much Has Mercury Shrunk?

    How Much Has Mercury Shrunk?

    What do many baked goods and the planet Mercury have in common? They shrink as they cool.

    Evidence suggests that since it formed about 4.5 billion years ago, Mercury has continuously contracted as it has lost heat. And somewhat like a fresh-baked cookie or cheesecake, Mercury also cracks as it cools: Thrust faults cut through the planet’s rocky surface to accommodate the ongoing shrinking.

    Continue Reading

  • Terence Stamp, Superman villain and star of The Adventures of Priscilla, Queen of the Desert, has died | Ents & Arts News

    Terence Stamp, Superman villain and star of The Adventures of Priscilla, Queen of the Desert, has died | Ents & Arts News

    British actor Terence Stamp – who famously played General Zod in Superman and Superman II – has died at the age of 87.

    The Oscar-nominated actor, who was born in London’s East End, also starred in hits such as Theorem, A Season in Hell, and The Adventures of Priscilla, Queen of the Desert.

    He formed one of Britain’s most glamorous couples with Julie Christie, with whom he starred in Far From the Madding Crowd in 1967.

    In a statement his family said he died on Sunday morning, adding: “He leaves behind an extraordinary body of work, both as an actor and as a writer that will continue to touch and inspire people for years to come.”

    Image:
    Stamp at the 2008 premiere of Valkyrie. Pic: Reuters

    Stamp received various accolades during his career, including a Golden Globe in 1962 for most promising newcomer for Billy Budd and a Cannes Film Festival best actor award in 1965 for The Collector.

    He also received Academy Award and BAFTA nominations for his performance in Billy Budd, as well as a second BAFTA nod in 1994 for his role in The Adventures of Priscilla, Queen of the Desert – which co-starred Hugo Weaving and Guy Pearce.

    Most recently, Stamp starred in director Edgar Wright’s Last Night in Soho. The 2021 psychological horror film also featured Diana Rigg, Anya Taylor-Joy and Matt Smith.

    Stamp in 2005. Pic: Reuters
    Image:
    Stamp in 2005. Pic: Reuters

    This breaking news story is being updated and more details will be published shortly.

    Please refresh the page for the latest version.

    You can receive breaking news alerts on a smartphone or tablet via the Sky News app. You can also follow us on WhatsApp and subscribe to our YouTube channel to keep up with the latest news.

    Continue Reading

  • Patients recall inadequate disclosure of electroconvulsive therapy risks

    Patients recall inadequate disclosure of electroconvulsive therapy risks

    The medical pros of electroconvulsive therapy (ECT) are being exaggerated while the risks are being downplayed, suggest the findings of a survey on the type of information patients and their relatives/friends recall having been given before the procedure, and published online in the Journal of Medical Ethics.

    Based on the responses, the researchers calculate that patients were nearly 4 times more likely to recall being told that resulting memory problems were temporary rather than long term. And they were 6 times more likely to recall being told that ECT can be life-saving rather than about potential heart problems.

    ECT involves inducing a brief, controlled seizure in the brain using electrical currents, usually given in 6 to 12 treatments under general anesthesia over several weeks, explain the researchers.

    Since its invention in 1938, ECT has remained a controversial procedure. And there is still no consensus on its medical pros and cons, exactly how it works–and for which mental health conditions-or the optimal dosing protocol, they add.

    In 2023, a joint report by the World Health Organization (WHO) and the United Nations confirmed that anyone offered ECT should be made aware of all its risks and potential short- and long-term risks, such as memory loss and brain damage.

    But recent audits of patient information leaflets on ECT in Australia and from across the UK suggest that the effectiveness of the treatment is often exaggerated while the risks are minimised, note the researchers.

    To find out what ECT recipients, and their relatives/friends, recall being told about the procedure, the researchers drew on the survey responses of a convenience sample of 858 ECT recipients and 286 relatives and friends from 44 countries, completed between January and September 2024.

    Most respondents were White and female. The average age at the time of their last ECT was 41, but ranged from 12 to 87. Most ECT recipients (73%) had their last ECT between 2010 and 2024. But for around 2% this dated back to between 1950 and 1969.

    The reasons given for the treatment included depression (73%); psychosis/schizophrenia (17%); bipolar disorder/mania (15%); catatonia (8%); other (13%); and ‘don’t know’ (6%).

    Respondents were asked if they remembered having been informed about the possible side effects of ECT, principally heart problems; temporary and long term memory problems, including greater susceptibility to these among women and older people; and the cognitive risks associated with serial general anaesthesia. 

    They were also asked if they remembered having been informed about their legal rights in relation to ECT, including that there’s no evidence ECT has any long-term benefits.

    And they were asked if they recalled being told (and misinformed) that: depression is caused by a chemical imbalance in the brain; ECT corrects this and other brain abnormalities; ECT can be life-saving/prevents suicide; it’s the most effective treatment for severe depression 

    Of the 735 ECT recipients who answered the question about the adequacy of the information received before the procedure, over half (59%) said this wasn’t adequate while 17% weren’t sure. 

    For example, nearly two thirds (63%) recall being told that ‘ECT can cause temporary memory problems’, but only 17% that it ‘can cause long term or permanent memory problems’. 

    Only 12% recall being told that ‘ECT can cause heart problems’ and 28% that there are ‘risks from repeated general anaesthesia’. 

    There were higher levels of recall around the information given about the definite benefits of ECT, although some of these benefits are disputed, say the researchers. 

    When asked to consider a list of items of misinformation, many recipients and relatives recall being told ‘depression is caused by a chemical imbalance in the brain’ (58% and 53%, respectively) and that ‘ECT corrects chemical imbalance or other brain abnormality’ (42% and 41%, respectively).

    Based on 682 ECT recipients who recalled at least one piece of information, the researchers calculated that they were nearly 4 times more likely to remember having been told about temporary memory problems as they were to have been told about long-term or permanent memory problems. 

    They were more than 5 times as likely to recall having been told ECT is the most effective treatment for severe depression as they were that there’s no evidence for any long-term benefits. And they were 6 times more likely to remember having been told that ECT can be ‘life saving/prevents suicide’ as they were about potential heart problems.

    Everyone was invited to include up to two other things they recalled clinicians telling them about ECT, if any: 363 ECT recipients, and 37 family/friends did so. The most common information reported (154 recipients and 11 family/friends) involved minimising memory loss or other side effects in various ways. 

    This included denial of any long-term effects (51) or simply stating that ECT is safe (34). Fifty one respondents recall being told ECT was the only option left for recovery, mostly because psychiatric drugs hadn’t worked. 

    This is a convenience sample and the researchers acknowledge that it may therefore not be representative of all ECT recipients. And those who were dissatisfied with their experience might have been more likely to fill in the survey.

    The responses also relied on personal recall, which, in a few cases, dated back to the 1950s. And events in the period just before ECT are particularly vulnerable to being lost because of the ECT, caution the researchers.

    Nevertheless, the findings align with those of previous studies, they point out. “The minimisation of risks, particularly long-term adverse effects, was pronounced, in both our quantitative and qualitative data,” they highlight, adding: “The legal implications of not ensuring informed consent are substantial.”

    They conclude: “These findings, in conjunction with previous studies, suggest an urgent need for greater efforts to ensure that patients and families are provided with comprehensive, balanced, evidence-based information when deciding whether to have ECT.”

    They suggest: “If efforts to persuade hospitals and clinics to comply with the ethical principIe of informed consent by providing balanced, comprehensive, evidence-based information are unsuccessful, professional, regulatory, and government organisations should intervene.”

    Source:

    Journal reference:

    Read, J., et al. (2025). A large exploratory survey of electroconvulsive therapy recipients, family members and friends: what information do they recall being given? Journal of Medical Ethics. doi.org/10.1136/jme-2024-110629.

    Continue Reading

  • A Study of Peripheral Arterial Disease in Type 2 Diabetes Mellitus Using the Ankle-Brachial Pressure Index and Its Correlation With Glycaemic Control and Duration of Diabetes in a Tertiary Care Teaching Hospital

    A Study of Peripheral Arterial Disease in Type 2 Diabetes Mellitus Using the Ankle-Brachial Pressure Index and Its Correlation With Glycaemic Control and Duration of Diabetes in a Tertiary Care Teaching Hospital


    Continue Reading

  • Knowledge, Attitude, and Screening of Kidney Disease Among Asymptomatic Healthcare Students at a Tertiary Healthcare Center in Coastal Andhra Pradesh

    Knowledge, Attitude, and Screening of Kidney Disease Among Asymptomatic Healthcare Students at a Tertiary Healthcare Center in Coastal Andhra Pradesh


    Continue Reading

  • Trial finds no cardiovascular benefit and higher safety risks with spironolactone in dialysis patients

    Trial finds no cardiovascular benefit and higher safety risks with spironolactone in dialysis patients

    A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving dialysis, despite earlier smaller studies suggesting benefit.

    The findings were published on August 14 in The Lancet and presented at ERA Congress 2025.

    The study enrolled 2,538 participants from 143 dialysis centres across 12 countries, making it the largest trial to date on spironolactone in people receiving dialysis. All participants had been on dialysis for at least three months and were either over 45 years old, or over 18 with diabetes.

    In people with normal kidney function, spironolactone reduces cardiovascular events. However, people receiving dialysis might not respond the same way to treatments proven effective in the general population. We launched the ACHIEVE study to determine the safety and effectiveness of spironolactone in people with kidney failure.”


    Michael Walsh, principal investigator of the study and senior scientist at the Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences

    Researchers tested whether a low daily dose (25 mg) of spironolactone could block aldosterone, a hormone that causes heart remodeling, fibrosis, and raises cardiovascular risk. They wanted to see if this treatment could lower the risk of cardiovascular death or hospitalization for heart failure in patients with kidney failure. “Aldosterone plays a harmful role in heart disease, and its levels tend to be high in dialysis patients,” Walsh said. “That’s why we thought spironolactone might help.”

    Instead, the drug showed no cardiovascular benefit, and it increased the risk of severe hyperkalaemia, a rise in blood potassium levels that can lead to irregular heart rhythms or even death in extreme cases. “Earlier studies suggested this type of medication might help people on dialysis, but they were small and had short follow-ups, unlike our large ACHIEVE study.”

    The trial began recruiting in 2018 and concluded in December 2024. Of the 3,565 patients recruited, 2,538 who tolerated the drug during a seven-week run-in period were randomly assigned to receive either 25 mg of spironolactone daily or a placebo. The trial was stopped early for futility after an independent monitoring committee determined there was little chance of seeing a meaningful benefit.

    Cardiovascular death or hospitalization for heart failure occurred in 258 patients in the spironolactone group, compared to 276 in the placebo group. The difference was not statistically significant. The study noted a potential difference in these incidents between men and women, although more research is needed to understand why:

    • Men: 163 (spironolactone) vs. 201 (placebo)
    • Women: 95 (spironolactone) vs. 75 (placebo)

    Severe hyperkalaemia occurred more often in the spironolactone group: 6.6 per cent of patients in the spironolactone group, compared to 4.5 per cent in the placebo group. “This can be a serious safety concern in an already vulnerable group,” Walsh added.

    Globally, an estimated 2.5 million people receive dialysis for kidney failure. Heart disease is the leading cause of death in this population, responsible for about 40 per cent of all deaths.

    “We really hoped that spironolactone could make a difference for people on dialysis,” said Walsh. “While the results are not what we wanted, they provide much-needed clarity. This study moves us one step closer to finding effective and safe treatments for a group that urgently needs them.”

    ACHIEVE was funded by the Canadian Institutes of Health Research, Medical Research Future Fund, Health Research Council, British Heart Foundation, PHRI, St. Joseph’s Healthcare Hamilton, Accelerating Clinical Trials Canada, CanSOLVE CKD, and Dalhousie Department of Medicine.

    Source:

    Journal reference:

    Walsh, M., et al. (2025). Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. The Lancet. doi.org/10.1016/S0140-6736(25)01198-5.

    Continue Reading

  • Kopecký wins ERC Barum Czech Rally Zlín

    Kopecký wins ERC Barum Czech Rally Zlín

    Driving a Škoda Fabia RS Rally2, the 2013 ERC champion, co-driven by Jiří Hovorka, secured a stunning 12th Barum win after edging Armstrong by 10.7sec across 13 challenging asphalt stages.

    “I’m shaking now because after last year I was not expecting I could be as fast as this during this year. For sure, thanks a lot to my co-driver and my team and to everyone because it has paid off,” said Kopecký.

    ERC title contender Andrea Mabellini boosted his championship hopes by claiming the final step on the podium, while championship leader Miko Marczyk finished seventh.

    Making a 20th start at the famous asphalt rally, Kopecký once again outlined his class proving to be the driver to beat, recording five stage wins on his way to victory.

    Mabellini caused an upset on Friday night by winning the Zlín super special but his time in the lead was short-lived. The Michelin-shod Škoda, driven by Kopecký, shot to the lead after winning SS2 on Saturday morning.

    It was a lead that Kopecký refused to give up for the remaining 11 stages, although it wasn’t a plain sailing run to victory. Kopecký came under pressure from Hyundai i20N driver Simon Wagner and Mabellini through Saturday, as his advantage was reduced to 1.2sec at midday service.

    Jon Armstrong claimed a second podium finish of the season

    © ERC

    Wagner was on course to steal the lead on Saturday afternoon before suffering a tyre deflation and a half spin in SS7 – the second run through Bunč – which dropped the Austrian out of the battle and down to fourth.

    Stage wins in both passes through Bunč helped M-Sport-Ford World Rally Team’s Armstrong vault from fifth to second, ending Saturday 6.5sec behind leader Kopecký.

    Armstrong, driving a Pirelli-equipped Ford Fiesta Rally2 managed to reduce the deficit to 6.3sec on Sunday morning, before Kopecký responded in front of his home crowd. The Czech driver managed to extend his lead through the remaining five stages as he completed an impressive victory.

    Armstrong equalled his best ERC result as the Irishman claimed his second podium of the season to help his title hopes.

    “What a weekend. I was pushing as much as I can. Yesterday I really enjoyed, today was honestly more of a struggle, more in my head to manage everything,” said Armstrong, who moved to third in the championship.

    Early leader Mabellini produced a strong drive throughout to claim third [+13.8sec] and the Power Stage win to cut the gap to Marczyk in the championship standings to 11 points [the gap calculated without Marczyk’s dropped score].

    “It is incredible. It seems like it is a dream to be in here fighting with Mr Barum [Jan Kopecký]. We must be proud of everything we have done,” said Mabellini.

    Andrea Mabellini moved to second in the championship standings

    Andrea Mabellini moved to second in the championship standings

    © ERC

    Wagner was unable to recover the lost ground on Saturday evening and had to settle for fourth, ahead Erik Cais, who delivered a series of fast stage times. Cais, driving Hyundai i20N Rally2, could have found himself in the podium fight had he avoided tyre damage on SS7 on Saturday evening.

    A gearbox issue hampered Filip Mareš on Sunday which resulted in the Hankook-shod Toyota GR Yaris Rally2 driver falling to sixth, ahead of Marczyk who struggled to find the pace required to challenge the front runners. The Polish driver salvaged two points from the Power Stage.

    “I’m not fully happy because we have had inconsistent pace. There were four or five good stages but also four or five that were below my expectations, and this is why we are fighting for seventh and not the podium places. I will fight [for the title] until the end,” said Marczyk.

    Local driver Adam Březík finished eighth, while Jakub Matulka and Mille Johansson rounded out the top 10.

    The rally proved to be particularly challenging for crews. Last year’s winner and qualifying pacesetter Dominik Stříteský was locked in the fight at the front until SS3 when an overshoot at a chicane triggered damage to three of his four wheels, that prompted an early retirement from fourth position.

    Championship leader Miko Marczyk on his way to finishing seventh

    Championship leader Miko Marczyk on his way to finishing seventh

    © ERC

    Miklós Csomós, making his return to ERC action, retired from the action after crashing out on SS2. Simone Tempestini also hit trouble on the same stage that resulted in the Romanian driver retiring with a suspension issue.

    Chris Ingram endured an eventful return to the stages after a nine month hiatus. The 2019 champion, running on MRF Tyres, reached the finish despite suffering multiple tyre deflations, a bent steering rack and a power steering issue.

    Philip Allen exited 11th position following an off-road excursion in SS6 that inflicted damage to the roll cage of his Škoda Fabia RS Rally2.

    Martin Vlček sealed victory in the Master ERC class with a 5m25.2sec advantage over Darius Biedrzyński. Hubert Kowalczyk took the ERC3 honours from Casey Jay Coleman by 43.8sec.

    Calle Carlberg sealed the Junior ERC title despite suffering a driveshaft failure that ended his rally victory bid on Saturday. The Junior ERC rally victory was claimed by Craig Rahill on his debut driving a Lancia Ypsilon Rally4 HF. Rahill beat Opel Corsa Rally4 driver Karl Peder Nordstrand by 35.9sec.

    The championship heads to Wales for the penultimate round at ERC JDS Machinery Rali Ceredigion from 5-7 September.

    Continue Reading

  • Famous Actress Khalil ur Rehman Wanted as Surraya

    Famous Actress Khalil ur Rehman Wanted as Surraya

    Khalil ur Rehman Qamar is a celebrated Pakistani writer known for his powerful storytelling and unforgettable dialogues. His iconic dramas include Pyarey Afzal, Sadqay Tumhare, Meray Paas Tum Ho, Mera Naam Yousuf Hai, Mohabbat Tumse Nafrat Hai, Zara Yaad Kar, Landa Bazar, and Laal Ishq. He has recently written Gentleman, which earned praise for its fresh storyline. Qamar’s latest drama, Main Manto Nahi Hoon, is currently airing on ARY Digital starring Humayun Saeed and Sajal Aly. The drama blends love, societal hypocrisy, and bold characters, reflecting Qamar’s signature style. His work continues to dominate Pakistani television, sparking admiration and debate alike.

    Famous Actress Khalil ur Rehman Wanted as Surraya

    Recently, the Main Manto Nahi Hoon writer gave an interview to Guryas Take in which he revealed the name of his most favourite famous actress he wanted to play Surraya.

    Famous Actress Khalil ur Rehman Wanted as SurrayaFamous Actress Khalil ur Rehman Wanted as Surraya

    Famous Actress Khalil ur Rehman Wanted as SurrayaFamous Actress Khalil ur Rehman Wanted as Surraya

    Famous Actress Khalil ur Rehman Wanted as SurrayaFamous Actress Khalil ur Rehman Wanted as Surraya

    Talking about it, Khalil Ur Rehman Qamar said, “I have a great love and respect for Saba Hamid, even though we argue a lot but that’s another story. Whenever I write, I keep Saba Hamid in mind. Initially, I was thinking of Saba only because I write challenging characters, and she is a brilliant actor. However, Nadeem asked me to consider Saima, which was also a wonderful option. Saima performed the role beautifully and with great skill.” Here is the link to the video:

    KRQ further added that Saima is an excellent actress who has a great command over her craft and that is the reason why whenever she appears on the screen, she leaves a mark through her remarkable performances.


    Continue Reading

  • Maxwell powers Australia to T20 series-clinching win over South Africa – The Himalayan Times – Nepal’s No.1 English Daily Newspaper

    Maxwell powers Australia to T20 series-clinching win over South Africa – The Himalayan Times – Nepal’s No.1 English Daily Newspaper

    CAIRNS, AUGUST 17

    Glenn Maxwell’s unbeaten half-century led Australia to a sensational two-wicket win over South Africa in the final T20 and clinched the series 2-1 on Saturday.

    With four needed off the final two balls, Maxwell reverse swiped Lungi Ngidi to third and stayed unbeaten on 62 off 36 balls as Australia reached 173-8 and denied South Africa its maiden T20 series win in Australia.

    Young T20 batting sensation Dewald Brevis had earlier made 53 off 26 balls that featured four sixes in one over off Aaron Hardie before Australia pulled back nicely and restricted the Proteas at 172-7.

    Both teams observed a minute of silence before the game and paid tribute to former Australia captain and coach Bob Simpson, who died at the age of 89.

    Captain Mitchell Marsh (54), who won the toss and elected to chase, and Travis Head had provided Australia a strong start of 66-1 in eight overs but South Africa stormed back with four wickets in four overs.

    Head couldn’t capitalize on an opportunity when South Africa skipper Aiden Markram couldn’t hold onto a tough return catch but the left-handed Head spooned an easy catch to short fine leg in the same over.

    Josh Inglis recovered from illness after missing out the last game but was clean bowled by Corbin Bosch off the first ball he faced. But Kwena Maphaka dealt a twin blow when both Marsh and Cameron Green couldn’t clear the fielders in the outfield as Australia slipped to 88-4 in the 11th over.

    Experienced fast bowler Kagiso Rabada then removed Tim David and Hardie in one over as Australia further slipped to 122-6 before Maxwell farmed the strike and shielded Ben Dwarshuis from the South African pacers.

    Dwarshuis contributed just 1 off six balls in a partnership of 41 with Maxwell as the power-hitter didn’t let the asking rate shoot up.

    With 12 needed off the last two overs, Bosch once again turned the game around with the wickets of Dwarshuis and Nathan Ellis off successive balls before Maxwell sealed the game by smashing two boundaries.

    “It was a little bit nerve wracking,” Maxwell said after hitting eight fours and two sixes in his player-of-the-match knock. “When we lost a couple of wickets in a row, Corbin Bosch bowled a brilliant over to sort of keep the run rate near 9 or 10 … and I probably had to do the majority of the striking, but it was it was nice to get a couple out of the middle (of the bat) right near the end.”

    Earlier, Brevis’ dismissal in the 12th over proved crucial for South Africa when Maxwell plucked a stunning diving catch at wide mid-on to end another blistering knock from a 22-year-old batter as the Proteas could add further 62 off the final 50 balls.

    Brevis hit six sixes and raised his half-century off just 22 balls when he smacked Hardie for four consecutive sixes before he was undone by Ellis’ short ball and Maxwell took a blinder.

    Ellis picked up 3-31 while Adam Zampa (2-24) also squeezed the runs in the middle overs and Josh Hazlewood chipping away with 2-30.

    Continue Reading

  • Chris Hemsworth hit with another major setback

    Chris Hemsworth hit with another major setback



    Chris Hemsworth hit with another major setback

    Chris Hemsworth hits with another setback as his wellness apps has closed its Australia office this week.

    The Thor star’s fitness app, Centr, has officially closed its Melbourne headquarters and lays off 15 Australian workers, as the company shifts its operations to the United States.

    A spokesperson for Centr confirmed to 9News that the “Melbourne office will no longer operate, and only a few Aussie employees will remain on board in remote roles”.

    “As Centr continues to scale globally, we’ve made the strategic decision to consolidate operations in the US to improve operational and geographic efficiency,” said an insider.

    “This transition affects 15 roles, with a few team members continuing remotely as part of the US–based team.”

    Nick Robinson, Centr’s digital general manager, stated that the “company plans to continue to drive towards business goals’ through ‘streamlining operations” and hiring top talent in the US.

    The drastic move came over a year after Chris sold the app for a reported $100 million to HighPost Capital, a private equity firm co-founded by Mark Bezos, who is the brother of Amazon billionaire Jeff Bezos.

    Meanwhile, the layoffs raised concerns considering the Avengers actor was seen holidaying in Spain and Ibiza with wife Elsa Pataky and their children in latest weeks.

    Continue Reading